Annexon, Inc. Files 8-K Report

Ticker: ANNX · Form: 8-K · Filed: Mar 4, 2024 · CIK: 1528115

Sentiment: neutral

Topics: 8-K, regulatory-filing, financial-exhibits

TL;DR

Annexon filed a routine 8-K, mostly procedural stuff.

AI Summary

On March 1, 2024, Annexon, Inc. filed an 8-K report. The filing primarily serves as a notification of an event and includes financial statements and exhibits. No specific material events or financial updates were detailed in the provided excerpt.

Why It Matters

This filing indicates Annexon, Inc. is making a regulatory disclosure and submitting financial exhibits, which is a standard procedural step for public companies.

Risk Assessment

Risk Level: low — The filing is a standard procedural 8-K and does not appear to disclose any new material risks or events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Annexon, Inc.?

The primary purpose of this 8-K filing is to serve as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating a Regulation FD Disclosure and the filing of Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on March 1, 2024.

What is Annexon, Inc.'s principal executive office address?

Annexon, Inc.'s principal executive office is located at 1400 Sierra Point Parkway, Bldg C, Suite 200, Brisbane, California 94005.

What is the SIC code for Annexon, Inc.?

The Standard Industrial Classification (SIC) code for Annexon, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

What is the filing date of this 8-K report?

The 8-K report was filed as of March 4, 2024.

Filing Stats: 580 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-03-04 17:25:36

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Annexon, Inc. Presentation. 104 Cover Page Interactive Data File, formatted in inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 4, 2024 Annexon, Inc. By: /s/ Jennifer Lew Jennifer Lew Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing